For example, CXCL9—a Th1 chemokine that recruits CD8+ T cells—is recognized as a biomarker for “immunologically hot” tumors and predicts positive response to immune checkpoint inhibitors (e.g., pembrolizumab) in triple-negative breast cancer [15,31]. Here, CXCL9 is linked to triple-negative breast carcinoma.